Variables in models can provide invaluable insights to disease

Article

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

Dr. Ambati defended animal models of age-related macular degeneration despite differences in eye structure and disease development between humans and other species often used in testing, such as primates, mice, and rabbits.

"Even imperfect models can provide invaluable insights," he said.

The validity of an animal model can be measured by several variables: face validity, or how well it copies the human condition; whether it obeys the genetic aspects of the disease; and how well it parallels the immunologic and pathogenetic mechanisms.

"This betrays the clinician's bias, but what is most important is how well it tells us something we didn't already know," Dr. Ambati said. "What does it predict, either about mechanisms or about treatment or diagnosis? Does it ultimately reveal some novel insights?"

He added that there is no single best choice of a model but that ongoing dialogue between basic scientists and clinical investigators will continue to lead to new discoveries.

He added that although mice lack maculas, several important insights have been gained from mouse models recently on issues such as development of choroidal neovascularization via substances found in drusen.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.